Table 3

Adverse events reported by participants who completed all study visits

Adverse Event

Study Visits


4-week

n/n (%)

8-week

n/n (%)

12-week

n/n (%)

24-week

n/n (%)


Throat irritation*

11/34 (32,4%)

5/32 (15,6%)

5/30 (16,7%)

4/27 (14,8%)


Mouth Irritation*

7/34 (20,6%)

4/32 (12,5%)

3/30 (10,0%)

2/27 (7,4%)


Sore Throat

4/34 (11,8%)

1/32 (3,1%)

1/30 (3,3%)

0/27 (0,0%)


Dry cough

11/34 (32,4%)

6/32 (18,8%)

3/30 (10,0%)

3/27 (11,1%)


Dry mouth

3/34 (8,8%)

1/32 (3,1%)

1/30 (3,3%)

1/27 (3,7%)


Mouth ulcers

1/34 (2,9%)

1/32 (3,1%)

1/30 (3,3%)

0/27 (0,0%)


Dizziness§

5/34 (14,7%)

2/32 (6,3%)

2/30 (6,7%)

1/27 (3,7%)


Headache

4/34 (11,8%)

2/32 (6,3%)

2/30 (6,7%)

1/27 (3,7%)


Nausea

5/34 (14,7%)

2/32 (6,3%)

1/30 (3,3%)

1/27 (3,7%)


* Throat and mouth irritation were described either as tickling, itching, or burning sensation

§ Dizziness, was also used to mean vertigo and light-headedness.

Polosa et al. BMC Public Health 2011 11:786   doi:10.1186/1471-2458-11-786

Open Data